Dostarlimab: From preclinical investigation to drug approval and future directions

Carlo Maria Cicala, Lucia Musacchio, Giovanni Scambia, Domenica Lorusso

Risultato della ricerca: Contributo in rivistaArticolo in rivista


Immune checkpoint blockers (ICB) act by reverting the immunosuppressive phenotype of cancer cells, thus allowing host immune system to generate an immune response to the tumor. One of the key mechanisms targeted by ICB is the PD-1/PD-L1 axis, which lies onto the interaction between the programmed-cell death protein 1 and its ligand, overexpressed in several tumor types. This interaction leads to the inhibition of T-cell proliferation and their apoptosis and exhaustion. Anti-PD-1/PD-L1 monoclonal antibodies are now the mainstay of treatment for several advanced stage tumors. Dostarlimab is a novel IgG4 anti-PD-1 antibody which has yielded remarkable results in mismatch-repair deficient endometrial cancer and locally advanced rectal cancer. This product review will illustrate the preclinical development of dostarlimab and its pharmacological characteristics, the clinical trials published so far and the ongoing clinical investigations.
Lingua originaleEnglish
pagine (da-a)1-10
Numero di pagine10
Stato di pubblicazionePubblicato - 2023


  • Dostarlimab
  • anti-PD-1
  • rectal cancer
  • immunotherapy
  • mismatch repair
  • endometrial cancer


Entra nei temi di ricerca di 'Dostarlimab: From preclinical investigation to drug approval and future directions'. Insieme formano una fingerprint unica.

Cita questo